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+
Tao Zhou, Ying Dang, Jacob J Baker, Jiajun Zhou and Yong-Hui Zheng*Abstract
Background: Vpr is exclusively expressed in primate lentiviruses and contributes to viral replication and disease
progression in vivo. HIV-1 Vpr has two major activities in vitro: arrest of cell cycle in the G2 phase (G2 arrest), and
enhancement of viral replication in macrophages. Previously, we reported a potent HIV-1 restriction in the human
CD4+ CEM.NKR (NKR) T cells, where wild-type (WT) HIV-1 replication was inhibited by almost 1,000-fold. From the
parental NKR cells, we isolated eight clones by limiting dilution. These clones showed three levels of resistance to
the WT HIV-1 infection: non-permissive (NP), semi-permissive (SP), and permissive (P). Here, we compared the
replication of WT, Vif-defective, Vpr-defective, and Vpu-defective viruses in these cells.
Results: Although both WT and Vpu-defective viruses could replicate in the permissive and semi-permissive clones,
the replication of Vif-defective and Vpr-defective viruses was completely restricted. The expression of APOBEC3G
(A3G) cytidine deaminase in NKR cells explains why Vif, but not Vpr, was required for HIV-1 replication. When the
Vpr-defective virus life cycle was compared with the WT virus life cycle in the semi-permissive cells, it was found
that the Vpr-defective virus could enter the cell and produce virions containing properly processed Gag and Env
proteins, but these virions showed much less efficiency for reverse transcription during the next-round of infection.
In addition, although viral replication was restricted in the non-permissive cells, treatment with arsenic trioxide
(As2O3) could completely restore WT, but not Vpr-defective virus replication. Moreover, disruption of Vpr binding to
its cofactor DCAF1 and/or induction of G2 arrest activity did not disrupt the Vpr activity in enhancing HIV-1
replication in NKR cells.
Conclusions: These results demonstrate that HIV-1 replication in NKR cells is Vpr-dependent. Vpr promotes HIV-1
replication from the 2nd cycle likely by overcoming a block at early stage of viral replication; and this activity does
not require DCAF1 and G2 arrest. Further studies of this mechanism should provide new understanding of Vpr
function in the HIV-1 life cycle.
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The vpr gene is highly conserved in the primate lenti-
viruses, which include HIV-1, HIV-2, and SIV (reviewed
in [1]). HIV-2 and some SIV strains additionally express
vpx, a vpr paralog acquired by gene duplication or non-
homologous recombination with an ancestral vpr gene
[2,3]. Both Vpr and Vpx proteins are incorporated into
nascent virions at a high copy number via an interaction
with Gag and consequently are present in the cytoplasm
of the target cells [4-8], indicating that they play a role* Correspondence: zhengyo@msu.edu
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reproduction in any medium, provided the orin the early stage of viral infection. In fact, inactivated
vpr genes quickly revert back to the active form after
infecting a human subject, chimpanzees, and rhesus
monkeys, indicating that vpr is under strong positive se-
lection [9,10]; vpr mutations are frequently found in
HIV-1 patients with slow disease progression [11-14];
vpr/vpx double-deletion mutation markedly attenuates
SIV replication in rhesus monkeys [15,16]; vpx single-
deletion mutation significantly attenuates SIV replication
in pig-tailed monkeys [17,18]. These results suggest that
vpr and vpx are very important for viral replication and
disease progression in vivo.
HIV-1 Vpr exhibits two major activities in vitro: in-
duction of G2 arrest and enhancement of viraltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(reviewed in [19,20]). Vpx does not induce G2 arrest,
but it enhances viral replication in both MDMs and
monocyte-derived dendritic cells (MDDCs) [21]. More
importantly, Vpx enhances HIV-1 replication in trans in
these myeloid cells [22,23]. The mechanism of Vpr-
induced G2 arrest has been thoroughly studied. Vpr
hijacks a host DNA-damage-response (DDR) pathway to
trigger G2 arrest by activating the DNA damage sensor
ATR but not ATM [24]. In particular, Vpr binds to the
DDB1-Cul4A-associated-factor-1 (DCAF1) protein,
which is recognized by the Cullin (Cul) 4A E3 ligase
consisting of Cul4A, RING H2 finger protein homolog
(RBX1), and DNA damage-binding protein 1 (DDB1)
(reviewed in [25]). It is currently considered that Vpr
triggers proteasomal degradation of an as-yet-unknown
cell cycle regulator, resulting in ATR-activation and G2
arrest [25]. The ATR-activation by Vpr also triggers
apoptosis [24] and the up-regulation of cell surface pro-
tein ULBP2 [26], which is a ligand for the natural killer
(NK) cell activation receptor NKG2D. Together, all these
downstream events may induce killing of infected cells
and contribute to viral pathogenesis in vivo.
Although both Vpr and Vpx enhance HIV-1 replication
in MDMs, their levels of enhancement are different, and
different mechanisms are involved. While initial experi-
ments showed that Vpr could only enhance HIV-1 repli-
cation by 2- to 5 -fold (reviewed in [27]), the activity of
Vpx could enhance replication by about 100-fold [28-30].
Vpr has several other activities in cell culture, including
activation of HIV-1 long-terminal-repeat (LTR), increase
of viral reverse transcription fidelity, and promotion of
viral DNA nuclear import [31]. Although all these activ-
ities could benefit viral replication, Vpr-enhanced nuclear
import seems to be more relevant for the viral replication
enhancement [27]. Vpx also enhances viral nuclear im-
port, but it promotes viral replication through DCAF1 by
overcoming a restriction factor that blocks viral reverse
transcription [29,30]. Recently, SAMHD1 was identified
as a myeloid cell-specific HIV restriction factor, which is
counteracted by Vpx [32,33].
It has been generally considered that Vpr and Vpx do
not promote viral replication in primary or immortalized
CD4+ T-cells. Nonetheless, several groups have reported
some levels of viral promotion: Vpr increases HIV-1
replication in human peripheral mononuclear cells
(PBMCs) or purified primary CD4+ T-cells by 2- to 6-
fold [34-36]; Vpr from a SIV strain that does not encode
Vpx enhances SIV replication in PBMCs by more than
10-fold [37]; Vpr and Vpx jointly enhance HIV-2 or SIV
replication in the human 174xCEM cell line or a simian
T-cell line by 10-fold [38,39]; Vpx alone enhances HIV-2
or SIV replication in PBMCs by more than 10-fold
[40,41]. These results strongly argue that Vpr shouldplay a positive role in HIV-1 infection of CD4+ T-cells
during natural infection. Because CD4+ T cells are the
primary targets for HIV-1 replication and the loss of
these lymphocytic cells is responsible for immunodefi-
ciency, we investigated how Vpr affects HIV-1 replica-
tion in these cells. Our efforts result in the identification
of human CD4+ T-cells where HIV-1 replication is com-
pletely dependent on Vpr. These results suggest an im-
portant Vpr function in HIV-1 replication, which was
not appreciated before.
Results
Vpr is required for HIV-1 replication in the permissive and
semi-permissive NKR clones
Previously, we reported a potent HIV-1 restriction in the
human CD4+ CEM.NKR (NKR) T cells [42]. NKR cells
express both CD4 and CXCR4, but their viral produc-
tion is typically 100-fold to 1000-fold lower than other
human T cells. However, we also found that although
the original NKR cells were clonally derived, they con-
tained heterogeneous populations that exhibit different
levels of HIV-1 resistance due to unknown variability.
From the original NKR cells, we isolated eight NKR sub-
clones that showed three levels of HIV-1 resistance: four
clones (N1, N2, N3, N6) were completely non-
permissive (NP); two (N7, N8) were semi-permissive
(SP); two (N4, N5) were highly permissive (P) [43]. As
can be seen, the viral production from N1-NP, N2-NP
and the original NKR cells was ~1,000-fold lower than
production from N5-P, and ~100-fold lower than pro-
duction from N8-SP and the original CEM cells
(Figure 1A). All these cells grew similarly (data not
shown), indicating that the differences in viral produc-
tion should not result from the differences in cell
division.
Because HIV-1 could replicate in N5-P and N8-SP
cells, we infected them with WT, Vif-defective (ΔVif),
Vpr-defective (ΔVpr), or Vpu-defective (ΔVpu) HIV-1;
and as controls, the human CD4+ T-cell line H9 and an-
other CEM-derived cell line CEM-SS (SS) were also
infected. As expected, it was found that in SS cells, all
four viruses replicated equally well (Figure 1B); in H9
cells, only the ΔVif virus did not replicate due to A3G
expression [44] (Figure 1C). In N5-P and N8-SP cells,
both the WT and ΔVpu viruses replicated well; the ΔVif
virus failed completely to replicate in N5-P and N8-SP
cells (Figure 1D, Figure 1E). It was not surprising that
the ΔVif virus did not grow, because these cells also
expressed A3G [43]. However, it was very surprising that
the ΔVpr virus replicated very slowly in the N5-P cells,
and like the ΔVif virus, it failed completely to replicate
in the N8-SP cells (Figure 1D, Figure 1E). Because
SAMHD1 was recently identified as a Vpx-sensitive re-
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Figure 1 Vpr is required for HIV-1 replication in the permissive and semi-permissive NKR clones. Wild-type (WT) HIV-1 (NL4-3) replication
was measured in NKR and its subclones by p24Gag ELISA (A). In addition, WT, ΔVif, ΔVpr, and ΔVpu HIV-1 replication was compared in SS (B), H9
(C), N5-P (D), and N8-SP (E) cells. Data represent one of at least three independent experiments. (F) Endogenous SAMHD1 expression in the
indicated cell lines was determined by Western blotting, and the amounts of actin were used as loading control.
Zhou et al. Retrovirology 2012, 9:93 Page 3 of 11
http://www.retrovirology.com/content/9/1/93limited to the myeloid tissues [32,33], we wondered
whether SAMHD1 played a role in these cells. However,
we could not detect SAMHD1 expression in NKR cells
and the other clones, but it was detected in THP1 cells
(Figure 1F). These results demonstrated that Vpr was
required for HIV-1 replication in the permissive and
semi-permissive NKR clones and that it did not target
SAMHD1.
Vpr is required for the 2nd round of infection
We then determined how Vpr promoted viral replication
in N8-SP and N5-P cells. First, we determined whether
Vpr was required for the 1st round of infection. HIV-1
luciferase (Luc) reporter viruses that only replicated one
cycle were produced from 293T cells in the presence or
absence of Vpr; their infectivity was measured in N8-SP,
N5-P, and SS cells (Figure 2A). It was found that both
Vpr(+) and Vpr(−) viruses produced similar levels of
luciferase activity in these cells (Figure 2B), and viral
production from these cells in the presence or absence
of Vpr was also quite similar (Figure 2C). These results
suggested that Vpr was not required during the 1st
round of viral replication.
Second, we determined whether Vpr was required for
the 2nd round of infection. N8-SP, N5-P, and SS cells
were infected with WT or ΔVpr virus. Newly produced
viruses were collected, and their infectivity was mea-
sured by infection of the HIV indicator TZM-b1 cells
(Figure 2D). It was found that Vpr did not increase HIV-
1 infectivity in SS cells, but it increased infectivitysignificantly in N8-SP cells and less significantly in N5-P
cells (Figure 2E). These results suggested that Vpr is
required for the 2nd round of viral replication.
Vpr enhances an early stage of viral replication at the
2nd round of infection
We next investigated how Vpr enhanced viral replication
during the 2nd round of infection. Since Vpr was
expressed in the producer cells in the previous experi-
ment, we expressed Vpr in the target cells, and tested
whether it could rescue the ΔVpr virus replication.
TZM-b1 cells were transfected with a pcDNA3.1 vector
expressing codon-optimized Vpr gene or an empty vec-
tor, and these cells were infected with ΔVpr HIV-1 pro-
duced from N8-SP, N5-P, and SS cells (Figure 3A). The
expression of Vpr in TZM-b1 cells was clearly detected
(Figure 3B). However, even in the presence of Vpr, the
ΔVpr HIV-1 infectivity did not increase in the target
cells (Figure 3C). This result suggested that Vpr should
be expressed from the producer cells to rescue the 2nd
round of HIV-1 replication in NKR cells.
Next, we determined whether the N8-SP and N5-P
cells produced defective particles in the absence of Vpr,
which would reduce viral infectivity during the 2nd cycle
of viral replication. N8-SP, N5-P, and another CEM-
derived CEM-T4 (T4) cells were infected with WT or
ΔVpr virus; virions were purified from culture superna-
tants by ultracentrifugation; Gag, Env, and Vpr expres-
sion in cells and virions was determined by Western
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Figure 2 Vpr is required for the 2nd round of infection. (A) Schematic illustration of the 1st round viral replication assay. WT or ΔVpr HIV-1
luciferase (Luc)-reporter viruses were produced by transfection of 293T cells with pNL-ΔGag plus pNL-Luc-ΔEnv, or pNL-ΔGagΔVpr plus pNL-Luc-
ΔEnvΔVpr vectors. After normalization by p24Gag ELISA, equal amounts of viruses were used to infect indicated cells. Two days later, viral
infectivity was determined by measuring the intracellular luciferase activity (B), or viral production from the supernatant by p24Gag ELISA (C). (D)
Schematic illustration of the 2nd round viral replication assay. Indicated cells were infected with VSV-G pseudotyped WT or ΔVpr HIV-1 (NL4-3) by
spinoculation. Three days later, virions were collected from supernatants, and equal amounts of virions were used to infect the HIV indicator TZM-
b1 cells. Thirty-six hours later, viral infectivity was determined by measuring the intracellular luciferase activity (E). The standard errors (S.E.) in (B)
and (E) were calculated from three independent experiments.
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that similar levels of processed Gag (p24) and Env
(gp120, gp41) were detected in both infected cells and
virions regardless of Vpr expression (Figure 3D). These
results suggested that these cells did not produce struc-
turally defective virions in the absence of Vpr, and nei-
ther did Vpr affect Gag, Pol, and Env expression.
Lastly, we analyzed the early stage of viral replication
during the 2nd cycle of infection. T4 cells were infected
with WT or ΔVpr virus purified from HIV-1-infected
N5-P, N8-SP, or T4 cells; twelve hours later, viral early
and late reverse transcription (RT) products were chased
by real-time PCR. It was found that the ΔVpr virus from
T4 cells generated slightly more early and late viral RT
products than the WT virus (Figure 3E). In contrast, the
ΔVpr virus from N5-P cells generated similar levels of
both RT products as the WT virus, whereas the ΔVprvirus from N8-SP cells generated 3- to 8-fold less of
both RT products than the WT virus. These results sug-
gested that Vpr should enhance an early stage of viral
replication during the 2nd cycle infection of these cells.
Vpr is also required for HIV-1 replication in the non-
permissive NKR clones
Furthermore, we determined whether Vpr was required
in the non-permissive clones as well as the parental
NKR cells. Because these cells were highly refractory to
HIV-1 infection, we first established a method to restore
viral replication. It was reported that arsenic could in-
crease HIV-1 replication in human cells, although the
mechanism for this activity remains unclear [45,46]. We
tested arsenic activity in these NKR cells by treatment
with As2O3. As2O3 is very toxic to human T cells be-













































Figure 3 Vpr enhances an early stage of viral replication at the 2nd round of infection. (A) Schematic illustration of the rescue of viral
replication assay by Vpr in target cells. Indicated cells were infected with VSV-G pseudotyped ΔVpr HIV-1 (NL4-3) by spinoculation. Three days
later, virions were collected from supernatants, and equal amounts of virions were used to infect the HIV indicator TZM-b1 cells, which were
transfected with a Vpr expression or control vector. The Vpr expression in TZM-b1 cells were determined by Western blotting (B), and viral
replication in TZM-b1 cells was determined by measuring the intracellular luciferase activity (C). (D) To analyze viral protein expression, indicated
cells were infected VSV-G pseudotyped WT or ΔVpr HIV-1 by spinoculation. Two days later, virions were purified from the culture supernatants by
ultracentrifugation. Viral protein expression in infected cells and virions was detected by Western blotting. (E) To analyze viral early and late
reverse transcription (RT), T4 cells were infected with WT or ΔVpr HIV-1 purified from spinoculated N5-P, N8-SP, and T4 cells, and 12 hours later,
viral early and late RT products were quantitated by real-time PCR. Copy numbers were presented as relative values after normalization with
mitochondrial DNA. The standard errors (S.E.) in (C) and (E) were calculated from three independent experiments.
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completely recovery of WT HIV-1 replication was found
in NKR, N1-NP, and N2-NP cells after this treatment
(Figure 4, top panels). In contrast, the same treatment
did not apparently affect WT HIV-1 replication in the
H9 cells. We then compared ΔVif, ΔVpr, and ΔVpu
virus replication in these treated cells. In H9 cells, the
ΔVif virus was the only one that did not grow, and the
As2O3 treatment had little influence on the replication
of these three viruses (Figure 4). In NKR, N1-NP, and
N2-NP cells, only the ΔVpu virus grew well in the pres-
ence of the As2O3 treatment; even under such treat-
ment, both ΔVif and ΔVpr viruses did not grow
(Figure 4). Thus, Vpr was also required for HIV-1 repli-
cation in the parental NKR cells and the non-permissive
clones.
To understand whether the Vpr-dependent HIV-1 rep-
lication was affected by viral tropism, we created a N2-
NP cell line expressing human CCR5 (N2-R5). A similar
cell line from SS was also created (SS-R5) to be the con-
trol. These cells were infected with R5-tropic WT or
ΔVpr HIV-1 strain NL-AD8, and viral replication wasdetermined. It was found that both WT and ΔVpr NL-
AD8 viruses replicated well in the SS-R5 cells, but they
failed completely to grow in the N2-R5 cells (Figure 5A).
When the N2-R5 cells were treated with As2O3, the WT
virus started to replicate, but the ΔVpr virus did not
(Figure 5A). Thus, the Vpr-dependency was not influ-
enced by viral tropism.
To understand whether the enhancement of HIV-1
replication by As2O3 was due to speeding up cell div-
ision, we compared the growth of NKR, N2-NP, and T4
cells in the presence or absence of 0.2 μM As2O3 treat-
ment. It was found that As2O3 slightly reduced their
growth rate, indicating that it might have some toxic ef-
fect at this concentration (Figure 5B). We also tried an-
other less-toxic arsenic compound (NaAsO2). NKR and
N2-NP cells were infected with WT or ΔVpr HIV-1 in
the presence of 2 μM NaAsO2 and viral replication was
measured. It was found that like the As2O3 treatment,
the NaAsO2 treatment also selectively increased the WT,
but not the ΔVpr HIV-1 replication (Figure 5C). These




































































































































Figure 4 Vpr is required for HIV-1 replication in the parental NKR cells and non-permissive clones. H9, NKR, N1-NP, and N2-NP cells were
infected with WT, ΔVif, ΔVpr, or ΔVpu HIV-1 (NL4-3) virus in the presence or absence of 0.2 μM As2O3. Viral replication in these cells was detected
by p24Gag ELISA. All experiments were repeated at least twice and consistent results were obtained.
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enhancement of viral replication
As introduced earlier, Vpr interacts with DCAF1 to in-
duce G2 arrest; although Vpx does not cause G2 arrest,
it interacts with DCAF1 to neutralize SAMHD1. We
wondered whether Vpr enhancement of viral replication
required DCAF1 and/or G2 arrest. We introduced two
well-characterized mutations (Q65R, R80A) into the vpr
gene in the proviral clone pNL4-3. The Vpr Q65R mu-
tant does not bind to DCAF1 and therefore does not in-
duce G2 arrest [49]; although the R80A mutant binds to
DCAF1, it does not induce G2 arrest [26,50].
First, we compared the expression and activity of these
Vpr proteins. The WT, ΔVpr, Q65R, and R80A viruses
were produced by transfecting 293T cells with these pro-
viral constructs. The Vpr expression in 293T cells was
determined by Western blotting; the G2 arrest activity
was determined by infection of SS and NKR with these
viruses. It was found that both Vpr Q65R and R80A
mutants were expressed at similar levels as the WTprotein (Figure 6A). In addition, the G2/G1 ratio in
ΔVpr and WT virus-infected cells shifted from 0.33 to
1.11 in the parental NKR cells and from 0.65 to 1.62 in
SS cells, indicating that Vpr induced strong G2 arrest in
these cells (Figure 6B). The background levels of G2 ar-
rest in the ΔVpr virus-infected cells were likely caused
by Vif, which also has similar activity [51]. Compared to
the WT virus, the levels of G2 arrest by the Q65R mu-
tant in SS and NKR cells were significantly reduced, and
these levels were further reduced in the R80A mutant
virus-infected cells (Figure 6B). These results were con-
sistent with previous observations made by other investi-
gators [26,49,50].
Second, we measured viral replication in SS, N8-SP,
N2-NP, and the parental NKR cells. Because the N2-NP
and parental NKR cells were highly non-permissive,
these cells were treated with As2O3 during infection. It
was found that in the SS cells, all these viruses replicated
equally well; in the N8-SP and arsenic-treated N2-NP


























































Figure 5 Viral tropism and Vpr-dependency. (A) SS-R5, N2-R5, and arsenic-treated N2-R5 cells were infected with R5-tropic WT or ΔVpr HIV-1
(NLAD8), and viral replication was detected by p24Gag ELISA. Data represent one of at least three independent experiments. (B) Measurement of
cell growth rate under As2O3 treatment. Indicated cells were treated with 0.2 μM As2O3 or untreated. Cell numbers were counted daily after
staining with trypan blue. (C) Effect of NaAsO2 on HIV-1 replication. Indicated cells were infected with WT or ΔVpr HIV-1 in the presence of 2 μM
NaAsO2 and viral replication was detected by p24
Gag ELISA.
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most equally well (Figure 6C). These results suggested
that both G2 arrest and DCAF1-binding should not be
required for Vpr enhancement of viral replication in
NKR cells.
Discussion
In this report, we present compelling evidence to dem-
onstrate that Vpr strongly enhances HIV-1 replication in
the human CD4+ NKR T-cells. The ΔVpr virus only pro-
duces baseline levels of virions in the semi-permissive
clone N8-NP, non-permissive clones N1-NP and N2-NP,
and parental NKR cells (~1 to 10 ng/ml p24Gag),
whereas the WT virus produces very high levels (100–
1000 ng/ml p24Gag) (Figure 1 and Figure 4). These
results suggest that Vpr could enhance HIV-1 replicationby 100- to 1000-fold in these cells, which is a much
greater effect than the previously reported Vpr effect in
macrophages and other CD4+ T-cells. In fact, this Vpr
effect is at the same level as that seen with Vif, highlight-
ing its important role in viral infection of CD4+ T-cells.
The mechanism of Vpr enhanced viral replication
reported here is different from what was reported before.
As introduced earlier, Vpr was shown to facilitate nu-
clear import of viral DNA in macrophages, which was
considered as a major mechanism for HIV-1 replication
enhancement [27]. We found that Vpr was not required
for viral replication during the 1st cycle of viral replica-
tion in NKR cells (Figure 2B, Figure 2C), indicating that
it did not promote viral replication at this step. Indeed,
Vpr was required for the 2nd cycle of viral replication
(Figure 2E). Vpr did not affect Gag and Env expression
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Figure 6 Vpr mutagenesis analyses. (A) Analysis of Vpr protein expression in viral producer cells. HIV-1 proviral vectors expressing indicated
Vpr proteins were transfected into 293T cells, and Vpr expression was determined by Western blotting. The amounts of actin were used as
loading control. (B) Analysis of cell cycle. SS and NKR cells were infected with HIV-1 expressing indicated Vpr proteins. After two days, intracellular
Gag proteins were stained with fluorescent antibodies and intracellular DNAs were stained with propidium iodide. The Gag-positive population
was sorted and analyzed for cell cycle profiles by flow cytometry. The G2/G1 ratios were calculated by dividing the proportion of cells in G2 and
M phases with that in G0 and G1 phases. (C) Replication of HIV-1 bearing Vpr mutations. SS, H9, N8-SP, and As2O3-treated N2-NP [N2 (+As)] and
NKR [NKR (+As)] cells were infected with HIV-1 expressing indicated Vpr proteins. Viral replication was detected by p24Gag ELISA. All experiments
were repeated at least twice and consistent results were obtained.
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aging (Figure 3D), indicating that it should not play a
role in viral entry. Nevertheless, the ΔVpr virus exhib-
ited poor efficiency in conducting reverse transcription,
indicating that viral replication should be blocked at an
early stage after entering into the cell. Using the parental
NKR cells, our previous work suggested that NKR cells
should express a dominant factor that inhibited the WT
virus replication from the 2nd cycle [42]. Since arsenic
could completely restore the WT viral replication, this
inhibitor was likely disrupted by arsenic. This arsenic-
sensitive inhibitor should not exist in the permissive and
semi-permissive clones, because the WT HIV-1 repli-
cated well in these cells without arsenic treatment.
Nevertheless, all NKR cells, with a possible exception for
the permissive clone N5-P, should express another Vpr-
sensitive inhibitor at high levels, because viral replication
in these cells was Vpr-dependent. Our results suggest
that this unknown factor should be packaged into vir-
ions and block an early stage of viral replication at the
2nd round of infection, because we found that Vpr was
required to be expressed in the viral producer cells and
rescued viral reverse transcription in the target cells
(Figure 2E, Figure 3C, Figure 3E). Recently, a genome-wide siRNA screening identified 52 new host factors that
could inhibit HIV-1 replication at the early stages of
viral life cycle [52]. It will be interesting to know how
they are expressed in NKR cells and whether they are
targeted by Vpr. Alternatively, Vpr may also recruit a
positive cellular factor from the viral producer cells into
HIV-1 virions that promotes the early stage of viral rep-
lication, although we showed before that NKR cells
should not be deficient in host factors to support HIV-1
replication [42].
To understand how Vpr counteracted this factor, we
tried to disrupt Vpr and DCAF1 interaction by introdu-
cing the Q65R mutation, and we found that this mutant
was still able to enhance viral replication (Figure 6C).
We also made the R80A mutant that still binds DCAF1
but does not induce G2 arrest according to the litera-
tures, and we found that it was also capable of enhan-
cing viral replication (Figure 6C). These results strongly
suggest that DCAF1 and G2 arrest are not required for
this Vpr activity. As introduced earlier, Vpx neutralizes
the restriction factor SAMHD1, and this activity is
DCAF1-dependent [32]. However, there is another un-
known HIV-1 restriction factor in MDDCs, which is
neutralized by Vpx in a DCAF1-indepednent manner
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hance HIV-1 replication in the human Hut78 T-cell line
and this activity was independent of DCAF1 [36]. Thus,
the Cul4A E3 ligase is not always required for Vpr and
Vpx activity.
Conclusion
We have identified human CD4+ T-cells where HIV-1
replication is completely dependent on Vpr. Vpr pro-
motes HIV-1 replication in NKR cells from the 2nd
round of infection, likely by overcoming an early block;
and its activity does not require DCAF1 and G2 arrest.
We suggest that further study of the Vpr activity in NKR
cells will provide new understanding of Vpr function in




The HIV reporter cell line TZM-b1, human T-cell lines
H9, Jurkat, CEM.NKR, and CEM-SS, and human mono-
cytic cell line THP1 were obtained from NIH AIDS Re-
search and Reference Reagent Program. 293T, U937, and
the original CEM cells (CCRF-CEM) were purchased
from ATCC. The CEM.NKR subclones N1, N2, N5, and
N8 were described before [43]. All T-cell and monocytic
cell lines were cultured in RPMI 1640 with 10% fetal bo-
vine serum (HyClone). 293T, and TZM-bI cells were
cultured in DMEM with 10% bovine calf serum
(HyClone).
To stably express human CCR5 in N2 and CEM-SS
cell lines, recombinant retrovirus expressing human
CCR5 was produced by transfection of 293T with retro-
viral vector pBABE.CCR5, packaging vector pCgp, and
VSV-G expression vector. Cells were then infected with
the virus and stable cell lines were selected by puro-
mycin (0.5 μg/ml).
Plasmids
The HIV-1 proviral constructs pNL-ΔVif, pNL-ΔVpr,
and pNL-ΔVpu were obtained from K. Tokunaga; pNL-
AD8 was obtained from E. Freed; pCgp was obtained
from P. Cannon; pBABE.CCR5 was obtained from N.
Landau through the NIH AIDS Research and Reference
Reagent Program; pcDNA3.1 expressing codon-
optimized Vpr was obtained from M.J. Lenardo [54].
The wild-type pNL4-3, the HIV-1 Env expression vector
pNL-ΔGag, and luciferase-reporter vector pNL-
LucΔEnv were described before [42,55]. pNL-AD8-ΔVpr,
pNL-ΔGagΔVpr, and pNL-Luc-ΔEnvΔVpr vectors were
created by swapping the AgeI/EcoRI fragment with the
pNL-ΔVpr vector. The Vpr Q65R and R80A mutations
were introduced into pNL4-3 by site-directed
mutagenesis.Virus production
HIV-1 virions were produced from 293T cells by the
standard calcium phosphate transfection. Typically, 20
μg proviral DNA were used to transfect 293T cells cul-
tured in a 100-mm dish with 40% confluence, and
viruses were collected from the supernatants after 48
hours. Viral production was measured by p24Gag ELISA.
HIV-1 infection of human T cell lines
A total of 2 × 105 cells were incubated with equal
amounts of virus at 37°C for three hours. After removal
of the inocula and washing three times, cells were cul-
tured in 24-well plates for 16 days. Culture supernatants
were then collected and replaced with new medium
every other day, and viral production was measured by
p24Gag ELISA. For spinoculation, cells were placed in a
48-well plate with the virus and centrifuged at 1,200 × g,
25°C, for 2 hours. Cells were washed and viral produc-
tion was determined similarly. After two days, viruses
were harvested from supernatants and purified by ultra-
centrifugation at 222,000 x g, 4°C, for 30 min. Virions
were then collected for Western blot analysis.
Real-time PCR analysis of viral cDNAs
A total amount of 200 ng virions purified from N5-P,
N8-SP, and T4 cells after spinoculation were inoculated
into 2 × 106 T4 cells at 37°C for 2 hours. Cells were then
washed with phosphate-buffered saline (PBS) and cul-
tured for additional 12 hours. The total cellular DNAs
were extracted from these cells by the DNeasy kit (Qia-
gen), and purified DNAs were further treated with DpnI
at 37°C for 1 hour to remove any plasmid DNA contam-
ination. Equal amounts of cellular DNAs were used for
real-time PCR using TaqManW Universal PCR Master
Mix kit (Applied Biosystems). The early reverse tran-
scripts (strong stop) were amplified by primers oHC64/
oHC65 and quantitated by a fluorescence labeled probe
oHC66; the late reverse transcripts were amplified by
MH531/MH532 and quantitated by LRT-P; mitochon-
drial DNA were amplified by MH533/MH 534 and
quantitated by mito-probe [56]. Reactions were per-
formed in triplicate. After initial incubation at 95°C for
10 minutes, 40 cycles of amplification were carried out
for 15 sec at 95°C followed by 1 minute at 60°C. Reac-
tions were analyzed using a 7900HT system (Applied
Biosystems). Finally, relative HIV-1 cDNA copies were
calculated by normalization to the levels of mitochon-
drial DNA.
Measurement of intracellular luciferase activity
After a 36-hour infection, cells were lysed in a buffer
(25 mM Tris–HCl, pH 7.8, 2 mM dithiothreitol, 2 mM
1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10%
glycerol, 1% Triton X-100). After removing the nuclei,
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http://www.retrovirology.com/content/9/1/93the cytosolic fraction was used to determine the firefly
luciferase activity with a luciferase assay kit (Promega).
Cell cycle analysis
1 × 106 cells were infected with HIV-1 with or without
Vpr mutations, respectively. Two days later, cells were
harvested and washed once with cold PBS. Washed cells
were resuspended in 1 ml of cold PBS, and then slowly
added into 9 ml of ice-cold 70% ethanol with gently vor-
texing. Ethanol-fixed cells were left overnight at −20°C.
The following day, cells were centrifuged at 500 × g to
remove ethanol and cells were washed with cold PBS
containing 0.1% Titon X-100 (PBS-T). Cells were then
incubated with 30 μl cold PBS-T containing 1 μl of anti-
Gag antibody (183-H12-5C) for 30 minutes. After wash-
ing two times with PBS-T, cells were incubated with 30
μl cold PBS-T containing 1 μl of FITC-conjugated anti-
mouse immunoglobulin antibody for another 30 min-
utes. After further washing, cells were resuspended in
PBS-T staining buffer containing 20 μg/ml propidium
iodide and 200 μg/ml RNase, and allowed to incubate
for two hours on ice. Cell cycle profiles were analyzed by
flow cytometry and results were analyzed by FlowJo to
derive percentages of cells in different phases of cell
cycle.
Western blotting
The anti-SAMHD1 antibody was perchased from Pro-
teintech Group. HIV-1 viral proteins were detected by
antibodies from NIH AIDS Research and Reference Re-
agent Program and their catalogue numbers are: 1513
(Gag), 526 (gp41), 521 (gp120), and 11836 (Vpr). Horse-
radish peroxidase (HRP)-conjugated anti-goat, rabbit, or
mouse immunoglobulin G secondary antibodies were
purchased from Pierce. Detection of the HRP-conjugated
antibody was performed using an enhanced chemilumin-
escence detection kit (Amersham Bioscience).
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